New metabolomic test could spot rare metabolic diseases faster

NCT ID NCT04201067

Completed Diagnosis Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new method called global metabolomic profiling to diagnose inborn errors of metabolism, a group of rare genetic disorders. Researchers compared this approach to traditional testing in 240 participants. The goal was to see if the new method could more accurately identify specific metabolic problems, which could lead to earlier and better treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this approach could lead to faster and more accurate diagnosis of rare metabolic disorders, helping guide treatment decisions.
What could go wrong: This is a completed diagnostic study, not a treatment trial. The approach may not be widely adopted or may not outperform existing methods in all cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONGENITAL DISORDERS OF GLYCOSYLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congenital disorder of glycosylation inborn errors of metabolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONGENITAL DISORDERS OF GLYCOSYLATION

Contacts and locations

Locations

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.